Pfizer Judge Certifies Class Action Over Celebrex, Bextra

Pfizer Inc. failed to block class-action status for investors who sued the world’s biggest drugmaker over claims it misled them about the prospects of two chronic pain-relief drugs, Celebrex and Bextra.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.